Phase II/III Study of FK949E: Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes
Latest Information Update: 19 Jun 2020
At a glance
- Drugs Quetiapine (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 06 Jun 2020 Results (n=322) assessing population-pharmacokinetic model of quetiapine XR formulation in patients with bipolar depression, published in the Clinical Therapeutics.
- 09 Aug 2016 Status changed from active, no longer recruiting to completed.
- 09 Jul 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.